Search clinical trials for: BI 695501 - higher concentration

Total 362 results

Boehringer Ingelheim

Completed

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

Healthy

United States
Boehringer Ingelheim

Completed

Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe

Arthritis, Rheumatoid

United States, Poland
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector

Healthy

Belgium
Boehringer Ingelheim

Terminated

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Belgium, Bulgaria, Germany, Greece, Netherlands, Poland, Portugal, Spain
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

Diabetic Nephropathies

Spain, Australia, United States, Canada, China, Japan, Malaysia, United Kingdom, Mexico, Portugal, Denmark, Hong Kong, Poland, New Zealand, Argentina, Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 685509 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated

Healthy

Korea, Republic of, Japan
Boehringer Ingelheim

Completed

Investigation of Single Rising Doses of BI 685509

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease

Chronic Kidney Disease

Spain, Canada, Australia, United States, Japan, Malaysia, United Kingdom, China, Mexico, Denmark, Russian Federation, Germany, Portugal, Hong Kong, Poland, Argentina, New Zealand, Sweden
Boehringer Ingelheim

Completed

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Diabetic Nephropathies

United States, Canada, Belgium, Czechia, Germany
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 685509 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live

Hypertension, Portal

Spain, Denmark, United Kingdom, Singapore, Germany, Italy, Austria, Canada, Croatia, China, Taiwan, Netherlands, Belgium, United States, Korea, Republic of, Japan, Argentina, France, Switzerland, Portugal, Israel, Romania
Boehringer Ingelheim

Completed

Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Spain, Korea, Republic of, Thailand, Malaysia, Poland, Russian Federation, Serbia, Bulgaria, Chile, Estonia, Germany, Hungary, Ukraine
Boehringer Ingelheim

Recruiting

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

Scleroderma, Systemic

United States, Belgium, Korea, Republic of, Australia, China, Taiwan, Spain, Israel, Japan, Mexico, Turkey, Germany, Italy, Brazil, France, Singapore, Canada, Philippines, United Kingdom, Switzerland, Finland, Greece, New Zealand, Den... and more
Boehringer Ingelheim

Completed

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Crohn Disease

Serbia, United Kingdom, United States, Czechia, Germany, Greece, Poland, Russian Federation, Turkey, Israel, Belarus, Ukraine, Croatia, Bosnia and Herzegovina
Boehringer Ingelheim

Completed

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Germany, Russian Federation, Czechia, Poland, Ukraine, Estonia, Slovakia
The Hospital for Sick Children
Canadian Institutes of Health Research (CIHR); Labatt Family Heart Centre

Completed

Optimizing Growth in Infants Receiving Modified Fat Breast Milk for the Treatment of Chylothorax

Chylothorax

Canada
Boehringer Ingelheim

Recruiting

A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems

Liver Diseases | Healthy

United States
Boehringer Ingelheim

Completed

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

Psoriasis

United States, Poland, Hungary, Germany, Latvia, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems

Hepatic Insufficiency | Healthy

United States
Boehringer Ingelheim

Completed

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

Spain, United States, Korea, Republic of, Malaysia, Poland, Thailand, Bulgaria, Chile, Estonia, Germany, Hungary, New Zealand, Russian Federation, Serbia, Ukraine
Boehringer Ingelheim

Recruiting

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Liver Cirrhosis | Hypertension, Portal

Germany, Spain, Japan, China, United States, Korea, Republic of, Canada, France, Austria, Romania
Medical University of South Carolina
National Institute on Drug Abuse (NIDA)

Completed

Impact of E-cigarette Characteristics on Reinforcement and Tobacco Use Patterns

Smoking | Tobacco Use

United States
Tan, Lijie

Unknown

The Optimal Intraoperative Supplemental Oxygen Administration During Minimally Invasive Esophagectomy

Oxygenation Index

China
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety in Healthy Volunteers

Healthy

Belgium, New Zealand
Chinese University of Hong Kong

Recruiting

High Concentration Oxygen for Pneumocephalus After Evacuation of Chronic Subdural Haematoma (HOPE)

Recurrence | Chronic Subdural Hematoma | Oxycephaly

Hong Kong
Sharp HealthCare
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants (DOXIE)

Respiratory Insufficiency | Hyperoxia | IVH- Intraventricular Hemorrhage | Extreme Prematurity | Hypoxia Neonatal

United States
Sunhawk Vision Biotech, Inc.

Completed

Phase 1 Study of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects

Myopia

Taiwan
Pontificia Universidad Catolica de Chile
Hospital Dr Sotero del Rio

Unknown

Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye

Dry Eye | Keratoconjunctivitis Sicca | Lacrimal Apparatus Diseases | Conjunctival Diseases | Keratitis | Corneal Diseases | Sjogren's Syndrome

Chile
Seikagaku Corporation

Completed

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye

Dry Eye Syndromes

United States
Althaia Xarxa Assistencial Universitària de Manresa

Terminated

Extubation Failure Prevention in High Risk Patients by High-flow Conditioned Oxygen Therapy vs. Standard Oxygen Therapy

Respiratory Failure

Spain
Boehringer Ingelheim

Withdrawn

Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects

Healthy

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
State University of New York at Buffalo

Completed

Anesthetic Gas Leakage in Children During Tonsillectomy: a Comparison of Cuffed and Uncuffed Tracheal Tubes

Exposure to Environmental Pollution | Adverse Effect of Unspecified General Anesthetic
Ataturk University

Recruiting

Effect of Higher Volume and Lower Dose on Analgesic Quality During Labor Analgesia With Dural Puncture Epidural

Analgesia

Turkey
Boehringer Ingelheim

Terminated

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Lymphoma, Non-Hodgkin

Austria, Belgium, United States, Bulgaria, Croatia, Czech Republic
University of Bath
Lucozade Ribena Suntory

Completed

Tea Extract, Blood Lipid and Dietary Fat

Diabetes | Lipid Metabolism

United Kingdom
Beijing Tiantan Hospital

Recruiting

Oxygen Concentration Target in Stroke Endovascular Treatment (Oxy-TARGET)

Ischemic Stroke

China
Amber Ophthalmics, Inc.

Recruiting

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries (EXPEDE)

Corneal Persistent Epithelial Defect

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
University of Aarhus

Completed

Temperature and Bicarbonate: Hemodynamic Effects During Dialysis (TURBO)

End Stage Renal Disease on Dialysis

Denmark
University of British Columbia
Canadian Institutes of Health Research (CIHR); Helen Keller International; Grand... and other collaborators

Completed

Thiamin Fortified Fish Sauce as a Means of Combating Infantile Beriberi in Rural Cambodia

Thiamin Deficiency

Cambodia
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
Yonsei University

Completed

Comparison of Image Quality of Coronary Computed Tomography Angiography bEtweeN High concenTRATion and Low concEntration Contrast Agents(CONCENTRATE Trial)

Coronary Artery Disease

Korea, Republic of
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Botanix Pharmaceuticals

Completed

A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States
The Hospital for Sick Children

Completed

Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal

Chronic Dialysis Patients

Canada
Santen Pharmaceutical Co., Ltd.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

Japan
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom

Search clinical trials for: BI 695501 - higher concentration

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations